Search

Displaying results 6581 - 6590 of 7022 in total
  1. Drug

    PX-478

    go.drugbank.com/drugs/DB06082
    Investigational

    PX-478 is a small molecule inhibitor of hypoxia inducible factor (HIF)-1 alpha currently in a clinical trial in patients with advanced metastatic cancer and lymphoma. PX-478 was effective in models of both non-small cell lung cancer and ...

  2. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  3. Drug

    CHF 4227

    go.drugbank.com/drugs/DB05882
    Experimental

    Additionally, the compound has shown no uterotrophic activity suggesting a potential therapeutic advantage over drugs normally used in postmenopausal therapy.

  4. Drug

    Riferminogene pecaplasmid

    go.drugbank.com/drugs/DB06394
    Investigational

    Riferminogene pecaplasmid (non-viral fibroblast growth factor 1; NV1FGF) is a recombinant DNA plasmid in a pCOR backbone allowing expression of human FGF1.

  5. Drug

    MX6

    go.drugbank.com/drugs/DB05789
    Experimental

    [3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid, 2-[3-(1-adamantyl)-4-methoxyphenyl]-5-benzimidazole carboxylic acid, and 6-[3-(1-adamantyl)-4,5-methylenedioxyphenyl]-2-naphthoic acid, can be used to

  6. Drug

    Magnesium orotate

    go.drugbank.com/drugs/DB13786
    Experimental

    It is a source of magnesium and is used as a mineral supplement to treat Mg deficiency. Orotic acid acts as a transporter that carries magnesium into the cells.

  7. Drug

    Vitex agnus-castus fruit extract

    go.drugbank.com/drugs/DB13193
    Investigational

    The main mechanism of action of vitex agnus-castus fruit extract has not been fully elucidated, however it is suggested to modulate the stress-induced prolactin secretion via dopaminergic actions, and

  8. Drug

    Implitapide

    go.drugbank.com/drugs/DB04852
    Investigational

    Implitapide is a microsomal triglyceride transfer protein (MTP)-inhibitor.

  9. Drug

    GO-203-2C

    go.drugbank.com/drugs/DB15008
    Investigational

    GO-203-2C is under investigation in clinical trial NCT02204085 (A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia).

  10. Drug

    OT-730

    go.drugbank.com/drugs/DB16112
    Investigational

    OT-730 is under investigation in clinical trial NCT00753168 (Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma).